Abstract
e14601 Background: After progression with Bevacizumab plus chemotherapy (chemo) in first-line treatment of metastatic colorectal cancer (mCRC), adding Bevacizumab (B) or Aflibercept (A) or Ramucirm...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have